Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.61 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.42 |
| ▸ | PARP1 | P09874 | 2/20 | 0.42 |
| ▸ | TSHR | P16473 | 2/20 | 0.39 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | PDE9A | O76083 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | BRD4 | O60885 | 7/20 | 0.36 |
| ▸ | USP2 | O75604 | 1/20 | 0.36 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9802990 | 0.98 | SMN1; SMN2 (0.57) | SMN1; SMN2ALOX15ALDH1A1MAPTPTK2 | |
| SCHEMBL5462185 | 0.83 | SMN1; SMN2 (0.48) | SMN1; SMN2ALOX15ALDH1A1MAPTPTK2 | |
| SCHEMBL23537289 | 0.79 | SMN1; SMN2 (0.38) | SMN1; SMN2ALOX15ALDH1A1MAPTPTK2 | |
| SCHEMBL23537463 | 0.79 | SMN1; SMN2 (0.42) | SMN1; SMN2ALOX15ALDH1A1MAPTPTK2 | |
| SCHEMBL21963156 | 0.76 | ALOX15 (0.91) | SMN1; SMN2ALOX15ALDH1A1MAPTPARP1 | |
| SCHEMBL9802964 | 0.72 | PTK2 (0.59) | SMN1; SMN2ALOX15ALDH1A1MAPTPTK2 | |
| SCHEMBL29824193 | 0.68 | PARP1 (0.59) | SMN1; SMN2ALOX15ALDH1A1MAPTPTK2 | |
| SCHEMBL23537356 | 0.68 | PARP1 (0.59) | SMN1; SMN2ALOX15ALDH1A1MAPTPTK2 | |
| SCHEMBL23537328 | 0.68 | PARP1 (0.64) | SMN1; SMN2ALOX15ALDH1A1PARP1DYRK1A | |
| SCHEMBL29824409 | 0.68 | PARP1 (0.64) | SMN1; SMN2ALOX15ALDH1A1PARP1DYRK1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230108906-A1 | SUBSTITUTED BICYCLIC AND TRICYCLIC UREAS AND AMIDES, ANALOGUES THEREOF, AND METHODS USING SAME | ARBUTUS BIOPHARMA CORPORATION (CA) | 2023-04-06 | — | — | US | disclosed |
| EP-4076648-A1 | SUBSTITUTED BICYCLIC AND TRICYCLIC UREAS AND AMIDES, ANALOGUES THEREOF, AND METHODS USING SAME | Arbutus Biopharma Corporation (CA) | 2022-10-26 | — | — | EP | disclosed |
| CN-115087486-A | Substituted bicyclic and tricyclic ureas and amides, analogs thereof, and methods of use thereof | 爱彼特生物制药公司 | 2022-09-20 | — | — | CN | disclosed |
| WO-2021127356-A1 | Substituted Bicyclic and Tricyclic Ureas and Amides, Analogues Thereof, and Methods Using Same | ARBUTUS BIOPHARMA, INC. (US) | 2021-06-24 | — | — | WO | disclosed |
| US-5068334-A | Analgesics and antipyretics | KARL THOMAE GMBH (DE) | 1991-11-26 | — | — | US | disclosed |
| EP-0338228-A2 | Use of quinoline-2,5-diones in a medicament having an analgesic, antipyretic and/or antiphlogistic activity | Dr. Karl Thomae GmbH (DE) | 1989-10-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230108906-A1 | SUBSTITUTED BICYCLIC AND TRICYCLIC UREAS AND AMIDES, ANALOGUES THEREOF, AND METHODS USING SAME | DDC, CDA, HMBS | SMN1; SMN2 4530/4885ALOX15 4219/4885ALDH1A1 3407/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.